Antibody Responses to Pneumococcal Vaccines Among HIV-infected Adults.

StatusCompleted
PhasePhase 2
Started

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Lead sponsor: French National Agency for Research on AIDS and Viral Hepatitis to ANRS, Emerging Infectious Diseases
    • Study sites: 0 to 1
    • Publications: 1 to 2
    v7
  2. Re-verified, no change to tracked fieldsv6
  3. Trial status: Terminated to Completedv5
  4. Trial status: Active, Not Recruiting to Terminated
    • Study completion date: Dec 2005 to Jan 2006
    v4
  5. 2 versions Re-verified since Oct 19, 2005, no change to tracked fieldsv2-v3
  6. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Streptococcus pneumoniae is the major cause of bacterial infection in HIV-infected patients. The current pneumococcal vaccine is poorly efficacious in patients with a CD4 cell count lower than 500/mm3. This study will test the efficacy and safety of a new pneumococcal vaccine strategy in patients with a CD4 cell count between 200 and 500/mm3.
Trial Details
NCT Number NCT00148824
Lead Sponsor ANRS, Emerging Infectious Diseases
Collaborators: Wyeth is now a wholly owned subsidiary of Pfizer
Conditions
(from sponsor)		 HIV Infections
Related terms HIV Infections
Enrollment 212 participants
Start Date
Study Completion (estimated)
Updated on ClinicalTrials.gov